Claims for Patent: 4,621,053

Summary for Patent: 4,621,053

Title:	Process for the production of human peptide hormones
Abstract:	Human peptide hormones, such as insulin, growth hormone, prolactin, adrenocorticotropic hormone, placental lactogen, calcitonin, parathyroid hormone and thyroid stimulating hormone, are produced by implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing the human peptide hormone in a non-human warm-blooded animal. After a period of time, the resultant tumor is extracted and disaggregated and then cultured in vitro under conditions appropriate to accumulate the human peptide hormone. The human.times.human hybridoma lymphoblastoid cell line is preferably formed by fusing parent human cells inherently capable of producing the human peptide hormone with a human lymphoblastoid line, preferably of leukemic origin. This process permits a substantial increase in the amount of human peptide hormone which can be produced.
Inventor(s):	Sugimoto; Kaname (Okayama, JP)
Assignee:	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (Okayama, JP)
Application Number:	06/584,017
Patent Claims:	1. In the process for producing human peptide hormone, excluding human erythropoietin, which comprises culturing human cells capable of producing a human peptide hormone on an in vitro nutrient medium under conditions appropriate to accumulate a substantial amount of the human peptide hormone, and recovering the accumulated human peptide hormone from the culture, the improvement, by which the amount of human peptide hormone produced during said in vitro culturing is substantially increased, comprising using as said human cells capable of producing a human peptide hormone, cells obtained by a process comprising: implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing said human peptide hormone in a non-human warm-blooded animal; feeding the animal to allow said human hybridoma cell line to utilize the nutrient body fluid of the animal for its multiplication; and extracting and disaggregating the resultant tumor, formed in the animal, for use in the in vitro production of said human peptide hormone. 2. A process as set forth in claim 1, wherein said human peptide hormone is human insulin. 3. A process as set forth in claim 1, wherein said human peptide hormone is human growth hormone. 4. A process as set forth in claim 1, wherein said human peptide hormone is human prolactin. 5. A process as set forth in claim 1, wherein said human peptide hormone is human adrenocorticotropic hormone. 6. A process as set forth in claim 1, wherein said human peptide hormone is human placental lactogen. 7. A process as set forth in claim 1, wherein said human peptide hormone is human thyroid-stimulating hormone. 8. A process as set forth in claim 1, wherein said human peptide hormone is human parathyroid hormone. 9. A process as set forth in claim 1, wherein said human peptide hormone is human calcitonin. 10. A process as set forth in claim 1, wherein said non-human warm-blooded animal is a fowl or a mammal. 11. A process as set forth in claim 1, wherein said non-human warm-blooded animal is a chicken, pigeon, dog, cat, monkey, goat, pig, cow, horse, rabbit, guinea pig, rat, nude rat, hamster, mouse or nude mouse. 12. A process as set forth in claim 14, wherein said fusing step comprises: suspending said parent human cells together with said human lymphoblastoid line in a salt solution containing an effective amount of a cell fusion inducing agent; allowing the resultant cell suspension to stand for a period sufficient to effect cell fusion; and selecting and cloning a hybridoma line capable of producing human peptide hormone. 13. A process as set forth in claim 12, wherein said cell fusion inducing agent is Sendai virus or polyethylene glycol. 14. A process as set forth in claim 1, wherein said human.times.human hybridoma lymphoblastoid cell line is obtained by fusing parent human cells inherently capable of producing a human peptide hormone with a human lymphoblastoid line. 15. A process as set forth in claim 14, wherein said parent human cells are normal or tumor human cells. 16. A process as set forth in claim 14, wherein said human peptide hormone is human insulin and said parent human cells are human insuloma cells. 17. A process as set forth in claim 14, wherein said human peptide hormine is human insulin and said parent human cells are human pancreas Langerhans island .beta.-cells. 18. A process as set forth in claim 14, wherein said human peptide hormone is human growth hormone and said parent human cells are human acidophile adenoma cells. 19. A process as set forth in claim 14, wherein said human peptide hormone is humanprolactin and said parent human cells are human acidophile adenoma cells. 20. A process as set forth in claim 14, wherein said human peptide hormone is human adrenocorticotropic hormone and said parent human cells are human chromophobe adenoma cells of the pituitary gland. 21. A process as set forth in claim 2, wherein said human peptide hormone is human placental lactogen and said parent human cells are human chorionic epithelioma cells. 22. A process as set forth in claim 14, wherein said human peptide hormone is humanplacental lactogen and said parent human cells are human syncytiotrophoblast cells from chorionic villi. 23. A process as set forth in claim 14, wherein said human peptide hormone is human thyroid-stimulating hormone and said parent human cells are human basophile adenoma cells. 24. A process as set forth in claim 14, wherein said human peptide hormone is human thyroid-stimulating hormone and said parent human cells are human chromophobe adenoma cells. 25. A process as set forth in claim 14, wherein said human peptide hormone is human parathyroid hormone and said parent human cells are human parathyroid tumor cells. 26. A process as set forth in claim 14, wherein said human peptide hormone is human parathyroid hormone and said parent human cells are human kidney carcinoma cells. 27. A process as set forth in claim 14, wherein said human peptide hormone is human parathyroid hormone and said parent human cells are human ovarian tumor cells. 28. A process as set forth in claim 14, wherein said human peptide hormone is human calcitonin and said parent human cells are human thyrophyma cells. 29. A process as set forth in claim 14, wherein said human peptide hormone is human calcitonin and said parent human cells are human carcinoid cells. 30. A process as set forth in claim 14, wherein said parent human cells are human lung carcinoma cells. 31. A process in accordance with claim 14, wherein said human lymphoblastoid line is of leukemic origin. 32. A process as set forth in claim 14, wherein said human lymphoblastoid line is a member selected from the group of cell lines consisting of Namalva, BALL-1, NALL-1, TALL-1 and JBL. 33. In the process for producing human peptide hormone, excluding human erythropoietin, which comprises culturing human cells capable of producing said peptide hormone on an in vitro nutrient medium under the conditions appropriate to accumulate a substantial amount of the human peptide hormone, and recovering the accumulated human peptide hormone from the culture, the improvement, by which the amount of human peptide hormone produced during said in vitro culturing is substantially increased, comprising using as said human cells capable of producing a human peptide hormone, cells obtained by a process comprising: suspending a human.times.human hybridoma lymphoblastoid cell line capable of producing said human peptide hormone in a device in which the nutrient body fluid of a non-human warm-blooded animal can be supplied to said human hybridoma cell line; embedding or placing said device in or on a non-human warm-blooded animal in a manner such that the nutrient body fluid of said animal is supplied to the human hybridoma cell line within said device; feeding the animal to allow said human hybridoma cell line to utilize the nutrient body fluid for its multiplication; and harvesting the multiplied human hybridoma cells from the device for use in the in vitro production of said human peptide hormone. 34. A process as set forth in claim 33, wherein said human peptide hormone is selected from the group consisting of human insulin, human growth hormone, human prolactin, human adrenocorticotropic hormone, human placental lactogen, human thyroid-stimulating hormone, human parathyroid hormone, and human calcitonin. 35. A process as set forth in claim 33, wherein said device is a diffusion chamber equipped with a membrane filter, ultra-filter or hollow fiber having a nominal pore size in the range of 10.sup.-7 -10.sup.-5 m. 36. A process as set forth in claim 33, wherein said non-human warm-blooded animal is a fowl or a mammal. 37. A process as set forth in claim 33, wherein said non-human warm-blooded animal is a chicken, pigeon, dog, cat, monkey, goat, pig, cow, horse, rabbit, guinea pig, rat, nude rat, hamster, mouse or nude mouse. 38. A process as set forth in claim 33, wherein said fusing step comprises: suspending said parent human cells together with said human lymphoblastoid line in a salt solution containing an effective amount of a cell fusion inducing agent; allowing the resultant cell suspension to stand for a period sufficient to effect cell fusion; and selecting and cloning a hybridoma line capable of producing human peptide hormone. 39. A process as set forth in claim 38, wherein said cell fusion inducing agent is Sendai virus or polyethylene. 40. A process as set forth in claim 33, wherein said human.times.human hybridoma lymphoblastoid cell line is obtained by fusing parent human cells inherently capable of producing a human peptide hormone with a human lymphoblastoid line. 41. A process as set forth in claim 40, wherein said parent cells are normal or tumor human cells. 42. A process as set forth in claim 40, wherein said human peptide hormone is human insulin and said parent human cells are human insuloma cells. 43. A process as set forth in claim 40, wherein said human peptide hormine is human insulin and said parent human cells are human pancreas Langerhans island .beta.-cells. 44. A process as set forth in claim 40, wherein said human peptide hormone is human growth hormone and said parent human cells are human acidophile adenoma cells. 45. A process as set forth in claim 40, wherein said human peptide hormone is humanprolactin and said parent human cells are human acidophile adenoma cells. 46. A process as set forth in claim 40, wherein said human peptide hormone is human adrenocorticotropic hormone and said parent human cells are human chromophobe adenoma cells of the pituitary gland. 47. A process as set forth in claim 40, wherein said human peptide hormone is human placental lactogen and said parent human cells are human chorionic epithelioma cells. 48. A process as set forth in claim 40, wherein said human peptide hormone is humanplacental lactogen and said parent human cells are human syncytiotrophoblast cells from chorionic villi. 49. A process as set forth in claim 40, wherein said human peptide hormone is human thyroid-stimulating hormone and said parent human cells are human basophile adenoma cells. 50. A process as set forth in claim 40, wherein said human peptide hormone is human thyroid-stimulating hormone and said parent human cells are human chromophobe adenoma cells. 51. A process as set forth in claim 40, wherein said human peptide hormone is human parathyroid hormone and said parent human cells are human parathyroid tumor cells. 52. A process as set forth in claim 40, wherein said human peptide hormone is human parathyroid hormone and said parent human cells are human kidney carcinoma cells. 53. A process as set forth in claim 40, wherein said human peptide hormone is human parathyroid hormone and said parent human cells are human ovarian tumor cells. 54. A process as set forth in claim 40, wherein said human peptide hormone is human calcitonin and said parent human cells are human thyrophyma cells. 55. A process as set forth in claim 40, wherein said human peptide hormone is human calcitonin and said parent human cells are human carcinoid cells. 56. A process as set forth in claim 40, wherein said parent human cells are human lung carcinoma cells. 57. A process in accordance with claim 40, wherein said human lymphoblastoid line is of leukemic origin. 58. A process as set forth in claim 40, wherein said human lymphoblastoid line is a member selected from the group of cell lines consisting of Namalva, BALL-1, NALL-1, TALL-1 and JBL.

Details for Patent 4,621,053

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2000-07-30
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2000-07-30
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2000-07-30
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2000-07-30
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2000-07-30